Starbucks CEO Brian Niccol on the rise of GLP-1s
Starbucks CEO Brian Niccol tells CNBC’s “Squawk on the Street” that the coffee chain has focused on making smaller, more “protein-focused” meals amid the rise of GLP-1 weight loss drugs.
Starbucks CEO Brian Niccol tells CNBC’s “Squawk on the Street” that the coffee chain has focused on making smaller, more “protein-focused” meals amid the rise of GLP-1 weight loss drugs.
